Coronary artery bypass surgery in patients with severe left ventricular dysfunction

C Selim Isbir1, Tekin Yildirim, Serdar Akgun

  • 1Department of Cardiovascular Surgery, Marmara University School of Medicine, Istanbul, Turkey.

Insights

Coronary artery bypass grafting (CABG) is feasible in patients with severe left ventricular dysfunction, offering acceptable mortality and encouraging mid-term survival. Preoperative intra-aortic balloon pump (IABP) support significantly improves outcomes.

Area of Science:

  • Cardiovascular Surgery
  • Cardiac Surgery
  • Interventional Cardiology

Background:

  • Severe left ventricular dysfunction presents significant challenges for cardiac surgery.
  • Coronary artery bypass grafting (CABG) is a potential treatment option for these high-risk patients.

Purpose of the Study:

  • To evaluate the role and outcomes of CABG in patients with ejection fraction (EF) below 30%.
  • To identify factors influencing survival in this patient cohort.

Main Methods:

  • A retrospective analysis of 212 patients with EF < 30% who underwent CABG.
  • Data collected on preoperative conditions, surgical techniques (including left internal mammary artery (LIMA) use and endarterectomy), and postoperative outcomes.
  • Follow-up for up to 58 months.

Main Results:

  • In-hospital mortality was 5.6%.
  • 1, 2, 3, and 4-year survival rates were 94%, 87%, 80%, and 73%, respectively.
  • Preoperative intra-aortic balloon pump (IABP) support significantly improved operative mortality (P=0.002), while LIMA use did not impact survival.

Conclusions:

  • CABG can be performed with acceptable mortality in patients with poor left ventricular function.
  • Mid-term survival results following CABG for severe left ventricular dysfunction are encouraging.
  • Preoperative IABP support is a critical factor in improving survival rates for these patients.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.